North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity
North America biopharmaceuticals market is projected to grow by 8.4% annually in the forecast period and reach $407.2 billion by 2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical trials and approvals for novel biomedicines, escalating healthcare spending, and favorable reimbursement policies.
Highlighted with 36 tables and 83 figures, this 153-page report “North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire North America biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies
o Granulocyte Colony Stimulating Factor
o P53 Protein
o P38 Protein
o Other Purified Proteins
o Amyloid Protein
o Defensin
o Transferrin
o Recombinant Insulin
o Other Recombinant Hormones
? Cancer Vaccines
? Malaria Vaccines
? Ebola Vaccines
? Hepatitis Vaccines
? Tetanus Vaccines
? Diphtheria Vaccines
? Cholera Vaccines
? Other Recombinant Vaccines
o Conventional Vaccines
? Polio Vaccines
? Pox Vaccines
? Other Conventional Vaccines
o Cyclase
o Caspase
o Cathepsin
o Autologous Products
o Acellular Products
o Other Products
Based on Testing Service, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
Highlighted with 36 tables and 83 figures, this 153-page report “North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire North America biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
- Monoclonal Antibodies
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies
- Recombinant Growth Factors
o Granulocyte Colony Stimulating Factor
- Purified Proteins
o P53 Protein
o P38 Protein
o Other Purified Proteins
- Recombinant Proteins
o Amyloid Protein
o Defensin
o Transferrin
- Recombinant Hormones
o Recombinant Insulin
o Other Recombinant Hormones
- Vaccines
? Cancer Vaccines
? Malaria Vaccines
? Ebola Vaccines
? Hepatitis Vaccines
? Tetanus Vaccines
? Diphtheria Vaccines
? Cholera Vaccines
? Other Recombinant Vaccines
o Conventional Vaccines
? Polio Vaccines
? Pox Vaccines
? Other Conventional Vaccines
- Recombinant Enzymes
o Cyclase
o Caspase
o Cathepsin
- Cell and Gene Therapies
o Autologous Products
o Acellular Products
- Synthetic Immunomodulators
- Other Product Types
o Other Products
Based on Testing Service, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
- Laboratory Testing
- Custom Testing/Customer Proprietary Testing
- Compendial and Multi Compendial Laboratory Testing
- Formulation Excipients
- Active Pharmaceutical Ingredients (API)
- Other Materials
- Innovative Biopharmaceuticals
- Biogenerics and Biosimilars
- Oncology
- Inflammatory and Infectious Diseases
- Autoimmune Disorders
- Metabolic Disorders
- Hormonal Disorders
- Cardiovascular Diseases
- Neurological Diseases
- Other Therapeutic Areas
- U.S.
- Canada
- Mexico
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 INTRODUCTION
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.1.3 Impact of Russia-Ukraine Conflict
2.1.4 Impact of Israel-Palestine War
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF NORTH AMERICA MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Monoclonal Antibodies
3.2.1 Anti-cancer Monoclonal Antibodies
3.2.2 Anti-inflammatory Monoclonal Antibodies
3.2.3 Other Monoclonal Antibodies
3.3 Recombinant Growth Factors
3.3.1 Erythropoietin
3.3.2 Granulocyte Colony Stimulating Factor
3.4 Purified Proteins
3.4.1 Leukemia Inhibitory Factor (LIF)
3.4.2 P53 Protein
3.4.3 P38 Protein
3.4.4 Other Purified Proteins
3.5 Recombinant Proteins
3.5.1 Serum Albumin
3.5.2 Amyloid Protein
3.5.3 Defensin
3.5.4 Transferrin
3.6 Recombinant Hormones
3.6.1 Recombinant Human Growth Hormones
3.6.2 Recombinant Insulin
3.6.3 Other Recombinant Hormones
3.7 Vaccines
3.7.1 Recombinant Vaccines
3.7.2 Conventional Vaccines
3.8 Recombinant Enzymes
3.8.1 Enterokinase
3.8.2 Cyclase
3.8.3 Caspase
3.8.4 Cathepsin
3.9 Cell and Gene Therapies
3.9.1 Allogenic Products
3.9.2 Autologous Products
3.9.3 Acellular Products
3.10 Synthetic Immunomodulators
3.11 Other Product Types
3.11.1 Blood Factors
3.11.2 Other Products
4 SEGMENTATION OF NORTH AMERICA MARKET BY TESTING SERVICE
4.1 Market Overview by Testing Service
4.2 Laboratory Testing
4.3 Custom Testing/Customer Proprietary Testing
4.4 Compendial and Multi Compendial Laboratory Testing
5 SEGMENTATION OF NORTH AMERICA MARKET BY RAW MATERIAL
5.1 Market Overview by Raw Material
5.2 Formulation Excipients
5.3 Active Pharmaceutical Ingredients (API)
5.4 Other Materials
6 SEGMENTATION OF NORTH AMERICA MARKET BY CLASSIFICATION
6.1 Market Overview by Classification
6.2 Innovative Biopharmaceuticals
6.3 Biogenerics and Biosimilars
7 SEGMENTATION OF NORTH AMERICA MARKET BY THERAPEUTIC AREA
7.1 Market Overview by Therapeutic Area
7.2 Oncology
7.3 Inflammatory and Infectious Diseases
7.4 Autoimmune Disorders
7.5 Metabolic Disorders
7.6 Hormonal Disorders
7.7 Cardiovascular Diseases
7.8 Neurological Diseases
7.9 Other Therapeutic Areas
8 NORTH AMERICA MARKET 2023-2033 BY COUNTRY
8.1 Overview of North America Market
8.2 U.S.
8.3 Canada
8.4 Mexico
9 COMPETITIVE LANDSCAPE
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
RELATED REPORTS
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.1.3 Impact of Russia-Ukraine Conflict
2.1.4 Impact of Israel-Palestine War
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF NORTH AMERICA MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Monoclonal Antibodies
3.2.1 Anti-cancer Monoclonal Antibodies
3.2.2 Anti-inflammatory Monoclonal Antibodies
3.2.3 Other Monoclonal Antibodies
3.3 Recombinant Growth Factors
3.3.1 Erythropoietin
3.3.2 Granulocyte Colony Stimulating Factor
3.4 Purified Proteins
3.4.1 Leukemia Inhibitory Factor (LIF)
3.4.2 P53 Protein
3.4.3 P38 Protein
3.4.4 Other Purified Proteins
3.5 Recombinant Proteins
3.5.1 Serum Albumin
3.5.2 Amyloid Protein
3.5.3 Defensin
3.5.4 Transferrin
3.6 Recombinant Hormones
3.6.1 Recombinant Human Growth Hormones
3.6.2 Recombinant Insulin
3.6.3 Other Recombinant Hormones
3.7 Vaccines
3.7.1 Recombinant Vaccines
3.7.2 Conventional Vaccines
3.8 Recombinant Enzymes
3.8.1 Enterokinase
3.8.2 Cyclase
3.8.3 Caspase
3.8.4 Cathepsin
3.9 Cell and Gene Therapies
3.9.1 Allogenic Products
3.9.2 Autologous Products
3.9.3 Acellular Products
3.10 Synthetic Immunomodulators
3.11 Other Product Types
3.11.1 Blood Factors
3.11.2 Other Products
4 SEGMENTATION OF NORTH AMERICA MARKET BY TESTING SERVICE
4.1 Market Overview by Testing Service
4.2 Laboratory Testing
4.3 Custom Testing/Customer Proprietary Testing
4.4 Compendial and Multi Compendial Laboratory Testing
5 SEGMENTATION OF NORTH AMERICA MARKET BY RAW MATERIAL
5.1 Market Overview by Raw Material
5.2 Formulation Excipients
5.3 Active Pharmaceutical Ingredients (API)
5.4 Other Materials
6 SEGMENTATION OF NORTH AMERICA MARKET BY CLASSIFICATION
6.1 Market Overview by Classification
6.2 Innovative Biopharmaceuticals
6.3 Biogenerics and Biosimilars
7 SEGMENTATION OF NORTH AMERICA MARKET BY THERAPEUTIC AREA
7.1 Market Overview by Therapeutic Area
7.2 Oncology
7.3 Inflammatory and Infectious Diseases
7.4 Autoimmune Disorders
7.5 Metabolic Disorders
7.6 Hormonal Disorders
7.7 Cardiovascular Diseases
7.8 Neurological Diseases
7.9 Other Therapeutic Areas
8 NORTH AMERICA MARKET 2023-2033 BY COUNTRY
8.1 Overview of North America Market
8.2 U.S.
8.3 Canada
8.4 Mexico
9 COMPETITIVE LANDSCAPE
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
RELATED REPORTS
LIST OF TABLES
Table 1. Snapshot of North America Biopharmaceuticals Market in Balanced Perspective, 2023-2033
Table 2. World Economic Outlook, 2024-2036
Table 3. World Economic Outlook, 2022-2024
Table 4. Scenarios for Economic Impact of Ukraine Crisis
Table 5. Scenarios for Economic Impact of Israel-Palestine War
Table 6. World Health Spending by Region, $ bn, 2013-2020
Table 7. Total Number of Registered Clinical Studies Worldwide, 2010-2021
Table 8. Worldwide Number of New Cancer by Type, 2020
Table 9. Main Product Trends and Market Opportunities in North America Biopharmaceuticals Market
Table 10. North America Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 11. North America Biopharmaceuticals Market: Monoclonal Antibodies by Type, 2023-2033, $ mn
Table 12. North America Biopharmaceuticals Market: Recombinant Growth Factor by Type, 2023-2033, $ mn
Table 13. North America Biopharmaceuticals Market: Purified Proteins by Type, 2023-2033, $ mn
Table 14. North America Biopharmaceuticals Market: Recombinant Proteins by Type, 2023-2033, $ mn
Table 15. North America Biopharmaceuticals Market: Recombinant Hormones by Type, 2023-2033, $ mn
Table 16. Selected Drugs for COVID-19 Treatment in Development, Nov 2022
Table 17. North America Biopharmaceuticals Market: Vaccines by Type, 2023-2033, $ mn
Table 18. North America Biopharmaceuticals Market: Recombinant Vaccines by Type, 2023-2033, $ mn
Table 19. North America Biopharmaceuticals Market: Conventional Vaccines by Type, 2023-2033, $ mn
Table 20. North America Biopharmaceuticals Market: Recombinant Enzymes by Type, 2023-2033, $ mn
Table 21. North America Biopharmaceuticals Market: Cell and Gene Therapies by Type, 2023-2033, $ mn
Table 22. North America Biopharmaceuticals Market: Other Product Types by Type, 2023-2033, $ mn
Table 23. North America Biopharmaceuticals Market by Testing Service, 2023-2033, $ mn
Table 24. North America Biopharmaceuticals Market by Raw Material, 2023-2033, $ mn
Table 25. North America Biopharmaceuticals Market by Classification, 2023-2033, $ mn
Table 26. North America Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 27. North America Biopharmaceuticals Market by Country, 2023-2033, $ mn
Table 28. U.S. Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 29. U.S. Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 30. Canada Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 31. Canada Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 32. Mexico Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 33. Mexico Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 34. Abbott Laboratories: Company Snapshot
Table 35. Abbott Laboratories: Business Segmentation
Table 36. Abbott Laboratories: Product Portfolio
Table 1. Snapshot of North America Biopharmaceuticals Market in Balanced Perspective, 2023-2033
Table 2. World Economic Outlook, 2024-2036
Table 3. World Economic Outlook, 2022-2024
Table 4. Scenarios for Economic Impact of Ukraine Crisis
Table 5. Scenarios for Economic Impact of Israel-Palestine War
Table 6. World Health Spending by Region, $ bn, 2013-2020
Table 7. Total Number of Registered Clinical Studies Worldwide, 2010-2021
Table 8. Worldwide Number of New Cancer by Type, 2020
Table 9. Main Product Trends and Market Opportunities in North America Biopharmaceuticals Market
Table 10. North America Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 11. North America Biopharmaceuticals Market: Monoclonal Antibodies by Type, 2023-2033, $ mn
Table 12. North America Biopharmaceuticals Market: Recombinant Growth Factor by Type, 2023-2033, $ mn
Table 13. North America Biopharmaceuticals Market: Purified Proteins by Type, 2023-2033, $ mn
Table 14. North America Biopharmaceuticals Market: Recombinant Proteins by Type, 2023-2033, $ mn
Table 15. North America Biopharmaceuticals Market: Recombinant Hormones by Type, 2023-2033, $ mn
Table 16. Selected Drugs for COVID-19 Treatment in Development, Nov 2022
Table 17. North America Biopharmaceuticals Market: Vaccines by Type, 2023-2033, $ mn
Table 18. North America Biopharmaceuticals Market: Recombinant Vaccines by Type, 2023-2033, $ mn
Table 19. North America Biopharmaceuticals Market: Conventional Vaccines by Type, 2023-2033, $ mn
Table 20. North America Biopharmaceuticals Market: Recombinant Enzymes by Type, 2023-2033, $ mn
Table 21. North America Biopharmaceuticals Market: Cell and Gene Therapies by Type, 2023-2033, $ mn
Table 22. North America Biopharmaceuticals Market: Other Product Types by Type, 2023-2033, $ mn
Table 23. North America Biopharmaceuticals Market by Testing Service, 2023-2033, $ mn
Table 24. North America Biopharmaceuticals Market by Raw Material, 2023-2033, $ mn
Table 25. North America Biopharmaceuticals Market by Classification, 2023-2033, $ mn
Table 26. North America Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 27. North America Biopharmaceuticals Market by Country, 2023-2033, $ mn
Table 28. U.S. Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 29. U.S. Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 30. Canada Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 31. Canada Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 32. Mexico Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 33. Mexico Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 34. Abbott Laboratories: Company Snapshot
Table 35. Abbott Laboratories: Business Segmentation
Table 36. Abbott Laboratories: Product Portfolio
LIST OF FIGURES
Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033
Figure 4. North America Biopharmaceuticals Market, 2023-2033, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of North America Biopharmaceuticals Market
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060
Figure 9. Worldwide Novel Active Substances (NASs) Launches by Therapeutic Area, 2013-2022
Figure 10. Primary Restraints and Impact Factors of North America Biopharmaceuticals Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of North America Biopharmaceuticals Market
Figure 13. Breakdown of North America Biopharmaceuticals Market by Product Type, 2023-2033, % of Revenue
Figure 14. North America Addressable Market Cap in 2024-2033 by Product Type, Value ($ mn) and Share (%)
Figure 15. North America Biopharmaceuticals Market by Product Type: Monoclonal Antibodies, 2023-2033, $ mn
Figure 16. North America Biopharmaceuticals Market by Monoclonal Antibodies: Anti-cancer Monoclonal Antibodies, 2023-2033, $ mn
Figure 17. North America Biopharmaceuticals Market by Monoclonal Antibodies: Anti-inflammatory Monoclonal Antibodies, 2023-2033, $ mn
Figure 18. North America Biopharmaceuticals Market by Monoclonal Antibodies: Other Monoclonal Antibodies, 2023-2033, $ mn
Figure 19. North America Biopharmaceuticals Market by Product Type: Recombinant Growth Factors, 2023-2033, $ mn
Figure 20. North America Biopharmaceuticals Market by Recombinant Growth Factor: Erythropoietin, 2023-2033, $ mn
Figure 21. North America Biopharmaceuticals Market by Recombinant Growth Factor: Granulocyte Colony Stimulating Factor, 2023-2033, $ mn
Figure 22. North America Biopharmaceuticals Market by Product Type: Purified Proteins, 2023-2033, $ mn
Figure 23. North America Biopharmaceuticals Market by Purified Proteins: Leukemia Inhibitory Factor (LIF), 2023-2033, $ mn
Figure 24. North America Biopharmaceuticals Market by Purified Proteins: P53 Protein, 2023-2033, $ mn
Figure 25. North America Biopharmaceuticals Market by Purified Proteins: P38 Protein, 2023-2033, $ mn
Figure 26. North America Biopharmaceuticals Market by Purified Proteins: Other Purified Proteins, 2023-2033, $ mn
Figure 27. North America Biopharmaceuticals Market by Product Type: Recombinant Proteins, 2023-2033, $ mn
Figure 28. North America Biopharmaceuticals Market by Recombinant Proteins: Serum Albumin, 2023-2033, $ mn
Figure 29. North America Biopharmaceuticals Market by Recombinant Proteins: Amyloid Protein, 2023-2033, $ mn
Figure 30. North America Biopharmaceuticals Market by Recombinant Proteins: Defensin, 2023-2033, $ mn
Figure 31. North America Biopharmaceuticals Market by Recombinant Proteins: Transferrin, 2023-2033, $ mn
Figure 32. North America Biopharmaceuticals Market by Product Type: Recombinant Hormones, 2023-2033, $ mn
Figure 33. North America Biopharmaceuticals Market by Recombinant Hormones: Recombinant Human Growth Hormones, 2023-2033, $ mn
Figure 34. North America Biopharmaceuticals Market by Recombinant Hormones: Recombinant Insulin, 2023-2033, $ mn
Figure 35. North America Biopharmaceuticals Market by Recombinant Hormones: Other Recombinant Hormones, 2023-2033, $ mn
Figure 36. North America Biopharmaceuticals Market by Product Type: Vaccines, 2023-2033, $ mn
Figure 37. North America Biopharmaceuticals Market by Vaccines: Recombinant Vaccines, 2023-2033, $ mn
Figure 38. North America Biopharmaceuticals Market by Vaccines: Conventional Vaccines, 2023-2033, $ mn
Figure 39. North America Biopharmaceuticals Market by Product Type: Recombinant Enzymes, 2023-2033, $ mn
Figure 40. North America Biopharmaceuticals Market by Recombinant Enzymes: Enterokinase, 2023-2033, $ mn
Figure 41. North America Biopharmaceuticals Market by Recombinant Enzymes: Cyclase, 2023-2033, $ mn
Figure 42. North America Biopharmaceuticals Market by Recombinant Enzymes: Caspase, 2023-2033, $ mn
Figure 43. North America Biopharmaceuticals Market by Recombinant Enzymes: Cathepsin, 2023-2033, $ mn
Figure 44. North America Biopharmaceuticals Market by Product Type: Cell and Gene Therapies, 2023-2033, $ mn
Figure 45. North America Biopharmaceuticals Market by Cell and Gene Therapies: Allogenic Products, 2023-2033, $ mn
Figure 46. North America Biopharmaceuticals Market by Cell and Gene Therapies: Autologous Products, 2023-2033, $ mn
Figure 47. North America Biopharmaceuticals Market by Cell and Gene Therapies: Acellular Products, 2023-2033, $ mn
Figure 48. North America Biopharmaceuticals Market by Product Type: Synthetic Immunomodulators, 2023-2033, $ mn
Figure 49. North America Biopharmaceuticals Market by Product Type: Other Product Types, 2023-2033, $ mn
Figure 50. North America Biopharmaceuticals Market by Other Product Types: Blood Factors, 2023-2033, $ mn
Figure 51. North America Biopharmaceuticals Market by Other Product Types: Other Products, 2023-2033, $ mn
Figure 52. Breakdown of North America Biopharmaceuticals Market by Testing Service, 2023-2033, % of Sales Revenue
Figure 53. North America Addressable Market Cap in 2024-2033 by Testing Service, Value ($ mn) and Share (%)
Figure 54. North America Biopharmaceuticals Market by Testing Service: Laboratory Testing, 2023-2033, $ mn
Figure 55. North America Biopharmaceuticals Market by Testing Service: Custom Testing/Customer Proprietary Testing, 2023-2033, $ mn
Figure 56. North America Biopharmaceuticals Market by Testing Service: Compendial and Multi Compendial Laboratory Testing, 2023-2033, $ mn
Figure 57. Breakdown of North America Biopharmaceuticals Market by Raw Material, 2023-2033, % of Sales Revenue
Figure 58. North America Addressable Market Cap in 2024-2033 by Raw Material, Value ($ mn) and Share (%)
Figure 59. North America Biopharmaceuticals Market by Raw Material: Formulation Excipients, 2023-2033, $ mn
Figure 60. North America Biopharmaceuticals Market by Raw Material: Active Pharmaceutical Ingredients (API), 2023-2033, $ mn
Figure 61. North America Biopharmaceuticals Market by Raw Material: Other Materials, 2023-2033, $ mn
Figure 62. Breakdown of North America Biopharmaceuticals Market by Classification, 2023-2033, % of Revenue
Figure 63. North America Addressable Market Cap in 2024-2033 by Classification, Value ($ mn) and Share (%)
Figure 64. North America Biopharmaceuticals Market by Classification: Innovative Biopharmaceuticals, 2023-2033, $ mn
Figure 65. North America Biopharmaceuticals Market by Classification: Biogenerics and Biosimilars, 2023-2033, $ mn
Figure 66. Breakdown of North America Biopharmaceuticals Market by Therapeutic Area, 2023-2033, % of Revenue
Figure 67. North America Addressable Market Cap in 2024-2033 by Therapeutic Area, Value ($ mn) and Share (%)
Figure 68. North America Biopharmaceuticals Market by Therapeutic Area: Oncology, 2023-2033, $ mn
Figure 69. North America Biopharmaceuticals Market by Therapeutic Area: Inflammatory and Infectious Diseases, 2023-2033, $ mn
Figure 70. North America Biopharmaceuticals Market by Therapeutic Area: Autoimmune Disorders, 2023-2033, $ mn
Figure 71. North America Biopharmaceuticals Market by Therapeutic Area: Metabolic Disorders, 2023-2033, $ mn
Figure 72. North America Biopharmaceuticals Market by Therapeutic Area: Hormonal Disorders, 2023-2033, $ mn
Figure 73. North America Biopharmaceuticals Market by Therapeutic Area: Cardiovascular Diseases, 2023-2033, $ mn
Figure 74. North America Biopharmaceuticals Market by Therapeutic Area: Neurological Diseases, 2023-2033, $ mn
Figure 75. North America Biopharmaceuticals Market by Therapeutic Area: Other Therapeutic Areas, 2023-2033, $ mn
Figure 76. Breakdown of North America Biopharmaceuticals Market by Country, 2023 and 2033, % of Revenue
Figure 77. Contribution to North America 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 78. U.S. Biopharmaceuticals Market, 2023-2033, $ mn
Figure 79. Venture Capital Deal Activity and Investment Flows in the U.S., 2013-2022, $ bn and Deal Counts
Figure 80. Canada Biopharmaceuticals Market, 2023-2033, $ mn
Figure 81. Biopharmaceuticals Market in Mexico, 2023-2033, $ mn
Figure 82. Growth Stage of North America Biopharmaceuticals Industry over the Forecast Period
Figure 83. Worldwide Top Ten Best-selling Biotech Drugs in 2022, $ bn
Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033
Figure 4. North America Biopharmaceuticals Market, 2023-2033, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of North America Biopharmaceuticals Market
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060
Figure 9. Worldwide Novel Active Substances (NASs) Launches by Therapeutic Area, 2013-2022
Figure 10. Primary Restraints and Impact Factors of North America Biopharmaceuticals Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of North America Biopharmaceuticals Market
Figure 13. Breakdown of North America Biopharmaceuticals Market by Product Type, 2023-2033, % of Revenue
Figure 14. North America Addressable Market Cap in 2024-2033 by Product Type, Value ($ mn) and Share (%)
Figure 15. North America Biopharmaceuticals Market by Product Type: Monoclonal Antibodies, 2023-2033, $ mn
Figure 16. North America Biopharmaceuticals Market by Monoclonal Antibodies: Anti-cancer Monoclonal Antibodies, 2023-2033, $ mn
Figure 17. North America Biopharmaceuticals Market by Monoclonal Antibodies: Anti-inflammatory Monoclonal Antibodies, 2023-2033, $ mn
Figure 18. North America Biopharmaceuticals Market by Monoclonal Antibodies: Other Monoclonal Antibodies, 2023-2033, $ mn
Figure 19. North America Biopharmaceuticals Market by Product Type: Recombinant Growth Factors, 2023-2033, $ mn
Figure 20. North America Biopharmaceuticals Market by Recombinant Growth Factor: Erythropoietin, 2023-2033, $ mn
Figure 21. North America Biopharmaceuticals Market by Recombinant Growth Factor: Granulocyte Colony Stimulating Factor, 2023-2033, $ mn
Figure 22. North America Biopharmaceuticals Market by Product Type: Purified Proteins, 2023-2033, $ mn
Figure 23. North America Biopharmaceuticals Market by Purified Proteins: Leukemia Inhibitory Factor (LIF), 2023-2033, $ mn
Figure 24. North America Biopharmaceuticals Market by Purified Proteins: P53 Protein, 2023-2033, $ mn
Figure 25. North America Biopharmaceuticals Market by Purified Proteins: P38 Protein, 2023-2033, $ mn
Figure 26. North America Biopharmaceuticals Market by Purified Proteins: Other Purified Proteins, 2023-2033, $ mn
Figure 27. North America Biopharmaceuticals Market by Product Type: Recombinant Proteins, 2023-2033, $ mn
Figure 28. North America Biopharmaceuticals Market by Recombinant Proteins: Serum Albumin, 2023-2033, $ mn
Figure 29. North America Biopharmaceuticals Market by Recombinant Proteins: Amyloid Protein, 2023-2033, $ mn
Figure 30. North America Biopharmaceuticals Market by Recombinant Proteins: Defensin, 2023-2033, $ mn
Figure 31. North America Biopharmaceuticals Market by Recombinant Proteins: Transferrin, 2023-2033, $ mn
Figure 32. North America Biopharmaceuticals Market by Product Type: Recombinant Hormones, 2023-2033, $ mn
Figure 33. North America Biopharmaceuticals Market by Recombinant Hormones: Recombinant Human Growth Hormones, 2023-2033, $ mn
Figure 34. North America Biopharmaceuticals Market by Recombinant Hormones: Recombinant Insulin, 2023-2033, $ mn
Figure 35. North America Biopharmaceuticals Market by Recombinant Hormones: Other Recombinant Hormones, 2023-2033, $ mn
Figure 36. North America Biopharmaceuticals Market by Product Type: Vaccines, 2023-2033, $ mn
Figure 37. North America Biopharmaceuticals Market by Vaccines: Recombinant Vaccines, 2023-2033, $ mn
Figure 38. North America Biopharmaceuticals Market by Vaccines: Conventional Vaccines, 2023-2033, $ mn
Figure 39. North America Biopharmaceuticals Market by Product Type: Recombinant Enzymes, 2023-2033, $ mn
Figure 40. North America Biopharmaceuticals Market by Recombinant Enzymes: Enterokinase, 2023-2033, $ mn
Figure 41. North America Biopharmaceuticals Market by Recombinant Enzymes: Cyclase, 2023-2033, $ mn
Figure 42. North America Biopharmaceuticals Market by Recombinant Enzymes: Caspase, 2023-2033, $ mn
Figure 43. North America Biopharmaceuticals Market by Recombinant Enzymes: Cathepsin, 2023-2033, $ mn
Figure 44. North America Biopharmaceuticals Market by Product Type: Cell and Gene Therapies, 2023-2033, $ mn
Figure 45. North America Biopharmaceuticals Market by Cell and Gene Therapies: Allogenic Products, 2023-2033, $ mn
Figure 46. North America Biopharmaceuticals Market by Cell and Gene Therapies: Autologous Products, 2023-2033, $ mn
Figure 47. North America Biopharmaceuticals Market by Cell and Gene Therapies: Acellular Products, 2023-2033, $ mn
Figure 48. North America Biopharmaceuticals Market by Product Type: Synthetic Immunomodulators, 2023-2033, $ mn
Figure 49. North America Biopharmaceuticals Market by Product Type: Other Product Types, 2023-2033, $ mn
Figure 50. North America Biopharmaceuticals Market by Other Product Types: Blood Factors, 2023-2033, $ mn
Figure 51. North America Biopharmaceuticals Market by Other Product Types: Other Products, 2023-2033, $ mn
Figure 52. Breakdown of North America Biopharmaceuticals Market by Testing Service, 2023-2033, % of Sales Revenue
Figure 53. North America Addressable Market Cap in 2024-2033 by Testing Service, Value ($ mn) and Share (%)
Figure 54. North America Biopharmaceuticals Market by Testing Service: Laboratory Testing, 2023-2033, $ mn
Figure 55. North America Biopharmaceuticals Market by Testing Service: Custom Testing/Customer Proprietary Testing, 2023-2033, $ mn
Figure 56. North America Biopharmaceuticals Market by Testing Service: Compendial and Multi Compendial Laboratory Testing, 2023-2033, $ mn
Figure 57. Breakdown of North America Biopharmaceuticals Market by Raw Material, 2023-2033, % of Sales Revenue
Figure 58. North America Addressable Market Cap in 2024-2033 by Raw Material, Value ($ mn) and Share (%)
Figure 59. North America Biopharmaceuticals Market by Raw Material: Formulation Excipients, 2023-2033, $ mn
Figure 60. North America Biopharmaceuticals Market by Raw Material: Active Pharmaceutical Ingredients (API), 2023-2033, $ mn
Figure 61. North America Biopharmaceuticals Market by Raw Material: Other Materials, 2023-2033, $ mn
Figure 62. Breakdown of North America Biopharmaceuticals Market by Classification, 2023-2033, % of Revenue
Figure 63. North America Addressable Market Cap in 2024-2033 by Classification, Value ($ mn) and Share (%)
Figure 64. North America Biopharmaceuticals Market by Classification: Innovative Biopharmaceuticals, 2023-2033, $ mn
Figure 65. North America Biopharmaceuticals Market by Classification: Biogenerics and Biosimilars, 2023-2033, $ mn
Figure 66. Breakdown of North America Biopharmaceuticals Market by Therapeutic Area, 2023-2033, % of Revenue
Figure 67. North America Addressable Market Cap in 2024-2033 by Therapeutic Area, Value ($ mn) and Share (%)
Figure 68. North America Biopharmaceuticals Market by Therapeutic Area: Oncology, 2023-2033, $ mn
Figure 69. North America Biopharmaceuticals Market by Therapeutic Area: Inflammatory and Infectious Diseases, 2023-2033, $ mn
Figure 70. North America Biopharmaceuticals Market by Therapeutic Area: Autoimmune Disorders, 2023-2033, $ mn
Figure 71. North America Biopharmaceuticals Market by Therapeutic Area: Metabolic Disorders, 2023-2033, $ mn
Figure 72. North America Biopharmaceuticals Market by Therapeutic Area: Hormonal Disorders, 2023-2033, $ mn
Figure 73. North America Biopharmaceuticals Market by Therapeutic Area: Cardiovascular Diseases, 2023-2033, $ mn
Figure 74. North America Biopharmaceuticals Market by Therapeutic Area: Neurological Diseases, 2023-2033, $ mn
Figure 75. North America Biopharmaceuticals Market by Therapeutic Area: Other Therapeutic Areas, 2023-2033, $ mn
Figure 76. Breakdown of North America Biopharmaceuticals Market by Country, 2023 and 2033, % of Revenue
Figure 77. Contribution to North America 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 78. U.S. Biopharmaceuticals Market, 2023-2033, $ mn
Figure 79. Venture Capital Deal Activity and Investment Flows in the U.S., 2013-2022, $ bn and Deal Counts
Figure 80. Canada Biopharmaceuticals Market, 2023-2033, $ mn
Figure 81. Biopharmaceuticals Market in Mexico, 2023-2033, $ mn
Figure 82. Growth Stage of North America Biopharmaceuticals Industry over the Forecast Period
Figure 83. Worldwide Top Ten Best-selling Biotech Drugs in 2022, $ bn
